SKINDEPTHDERM.COM

Researchers wanted to know whether tralokinumab also works by combating the microbial dysbiosis component of AD, since 90% of those with AD are colonized with high levels of S. aureus and lack microbial diversity seen in normal skin. In the double-blind, randomized, placebo-controlled ECZTRA 1 trial, 802 adults with moderate-to-severe AD were randomized 3:1 to 300 mg subcutaneous tralokinumab or placebo for 52 weeks... Disseminated superficial actinic porokeratosis (DSAP) is a variant of porokeratosis that predominantly affects sun-exposed areas starting in the 3rd to 4th decade. Although most commonly benign, DSAP holds the potential for malignant transformation. Currently, treatment for DSAP is very challenging. This double-blind clinical trial randomized 31 participants with DSAP to receive topical lovastatin 2% cream (n=14) or topical lovastatin 2% plus cholesterol 2% cream (n=17) for 12 weeks. Disease severity was analyzed at baseline and 12-weeks using the DSAP General..